Layer Tesamorelin onto a primed system to attack visceral fat.
By the end of Week 4 your pituitary is no longer responding to Ipamorelin and CJC-1295 (no-DAC) like a deconditioned organ. The nightly GH pulse is established, IGF-1 has shifted upward, ghrelin signaling is no longer a panic-eating problem, and — most importantly — your fasting insulin should now be at or below your pre-protocol baseline. That last variable is the gate. The reason Phase 2 is staged here and not on Day 1 is that the GH axis and the insulin axis sit on opposite ends of the same metabolic seesaw. The practitioner corpus is explicit on this: GH analogues — Ipamorelin, CJC-1295, Tesamorelin — can worsen insulin resistance in a patient whose baseline insulin is already elevated. You don't layer the most aggressive GH-releasing peptide in the stable onto an insulin-resistant substrate. You prime, then you layer.
What's actually happening when Tesamorelin enters the stack
Tesamorelin is a stabilized GHRH analog — chemically modified releasing hormone — engineered to survive longer in circulation than endogenous GHRH while binding the same pituitary GHRH receptor. It does not act on the ghrelin pathway (Ipamorelin's lane). It does not flood the system with a long DAC tail (CJC-1295-DAC's lane). What it does is generate a sharp, clean, GHRH-driven GH pulse that selectively mobilizes visceral adipose tissue.
The substrate is uniquely loaded on this compound for one reason: it is the only GH secretagogue in the stable with full FDA approval and Phase III double-blind placebo-controlled data behind it. The pivotal trials in HIV-associated lipodystrophy patients with dorsocervical fat deposits showed a roughly 50 cm² reduction in cross-sectional visceral adipose tissue at Week 26 in responders, alongside parallel reductions in waist circumference and serum triglycerides. The mechanism translates: VAT is uniquely sensitive to lipolytic GH signaling because visceral adipocytes express a higher density of β-adrenergic and GH receptors than subcutaneous adipocytes. When GH peaks rise — pulsatile, not sustained — visceral fat is the first depot to release free fatty acids.
The reason Tesamorelin out-performs Ipamorelin or CJC-1295 alone for the cutting phase is the amplitude of the GH pulse and the receptor profile of the depot you're targeting. Ipamorelin gives you a clean nighttime pulse for sleep, recovery, and gentle body-recomposition signaling. CJC-1295 (no-DAC) extends and amplifies natural GHRH waves. Tesamorelin slams a high-amplitude GHRH-driven pulse into a pituitary that's already been conditioned for four weeks. The visceral depot — the abdominal beer-belly fat, the dorsocervical pad, the perinephric fat — is where this pulse cashes out.
A second mechanism the corpus flags repeatedly: Tesamorelin lowers serum triglycerides. The lipolytic clearance of VAT shifts the liver's substrate balance, reducing VLDL output. This is why the cardiometabolic markers — triglycerides, ApoB, visceral fat on DEXA — move in concert during a Tesamorelin run, not just the waist tape.
The Phase 2 stack
| Compound | Dose | Route | Frequency | Evidence Tier | Notes |
|---|---|---|---|---|---|
| Tesamorelin | 1 mg | Subcutaneous, abdomen | 1x daily, 5 days/week (Mon–Fri) | 🔵 Clinical | FDA-approved for lipodystrophy. Inject AM on empty stomach. Two days off prevents pituitary downregulation. |
| Ipamorelin | 100–200 mcg | Subcutaneous, abdomen | 1x daily, before bed, 7 days/week | 🟢 Expert | Maintain from Phase 1. Empty stomach (≥2 hrs post-meal). Nighttime pulse stacks with natural SWS GH surge. |
| CJC-1295 (no DAC / Mod GRF 1-29) | 100 mcg | Subcutaneous, abdomen | Co-administered with Ipamorelin at bedtime | 🟢 Expert | Same syringe is fine. GHRH + GHRP synergy — the "one-two punch" the corpus describes. |
| Reconstitution standard | 5 mg Tesa in 2 mL BAC | — | — | — | Each 0.4 mL = 1 mg. Refrigerate after reconstitution; stable ~14 days. |
Two protocol variants the substrate sanctions for Tesamorelin specifically:
- 1 mg, 1–2x/day, 5 days per week — the standard pivotal-trial-derived schedule.
- 5 mL of 1 mg/0.6 mL solution, 1x/day, 6 days per week — the higher-frequency variant used in cosmetic VAT-reduction protocols.
The first is what most practitioners run for a cutting phase. The second is reserved for established responders pushing for accelerated VAT clearance.
Week-by-week — what the substrate says you should feel
- Week 5 — Injection site reactions are the most consistently reported early signal. Mild erythema, slight wheal, occasional bruising at the abdominal site. This is mechanism-confirming, not pathology. Rotate sites daily.
- Week 6 — Waist circumference begins to drop before the scale does. Practitioner consensus: 0.5–1 cm reduction at the umbilicus by end of Week 6 in responders. Sleep quality continues to deepen from the maintained Ipamorelin pulse.
- Week 7–8 — Triglycerides re-checked at Week 8 will typically show meaningful movement downward. This is the lagging lab indicator that confirms VAT lipolysis is happening systemically, not just regionally.
- Week 9–10 — Dorsocervical fat (upper-back/neck pad), if present, visibly softens. This is the most Tesamorelin-specific aesthetic signature in the corpus.
What's NOT happening yet
- Subcutaneous fat is not melting. Tesamorelin's selectivity is the point. The flank and lower-abdomen pinch will be slower than the visceral compartment. Don't grade the protocol by mirror-pinch.
- Lean mass is not exploding. The GH-axis stack is body-recomp, not anabolic-loading. If lean mass is the goal, IGF-1 LR3 or a different compound class is the lever — not more GHRH.
- Hunger is not vanishing. Ipamorelin produces mild ghrelin-pathway hunger; Tesamorelin is hunger-neutral. Net effect: appetite is slightly elevated vs. baseline. If you're running a cut, this is a discipline window, not a peptide failure.
- Fasting glucose may rise 5–10 mg/dL. GH antagonizes insulin. This is expected and reversible. If fasting glucose rises >15 mg/dL or HbA1c trends above 5.7, stop, recheck insulin sensitivity, and re-stage before continuing.
- You are not on this stack forever. The pivotal data is on 26-week courses. Practitioner consensus runs 10–12 weeks before a deload. Continuous high-amplitude GHRH stimulation desensitizes the pituitary and erodes the response curve.
The labs to pull at Week 8 are non-negotiable: fasting insulin, fasting glucose, HbA1c, IGF-1, triglycerides, ApoB. The first three tell you whether the insulin-axis trade-off is acceptable. IGF-1 tells you the stack is biologically active (target: upper third of age-adjusted range, not above it). Triglycerides and ApoB tell you the VAT is actually clearing systemically.
Research describes this response curve in lipodystrophy populations. Your physiology is not theirs. Track the labs, watch the waist, adjust.